Angiogenesis inhibition by transdominant mutant Ets-1

Area of Science:

• Molecular Biology
• Cell Biology
• Biotechnology

Background:

• Endothelial cells (ECs) express transcription factor Ets-1 when stimulated by angiogenic factors.
• Ets-1 promotes an angiogenic and invasive phenotype in ECs, driving blood vessel formation.
• Controlling angiogenesis is crucial for treating diseases characterized by excessive or insufficient blood vessel growth.

Purpose of the Study:

• To develop a dominant-negative inhibitor of Ets-1 to control angiogenesis.
• To assess the efficacy of the transdominant mutant Ets-1 (TMEts-1) in inhibiting EC angiogenic activities.
• To evaluate the in vivo anti-angiogenic potential of TMEts-1 delivered via an adenovirus vector.

Main Methods:

• Construction of a transdominant mutant Ets-1 (TMEts-1) designed to inhibit wild-type Ets-1 activity.
• Stable transfection of murine endothelial cell line MSS31 with the TMEts-1 gene.
• Assessment of angiogenic properties (proliferation, migration, invasion, tube formation) in vitro.
• In vivo evaluation of anti-angiogenic effects using AdTMEts-1 in Matrigel plugs in C57BL mice.

Main Results:

• TMEts-1 effectively inhibited the DNA binding and transactivation of wild-type Ets-1.
• Transfection with TMEts-1 significantly impaired EC proliferation, migration, invasion, and tube formation in vitro.
• Adenovirus-mediated delivery of TMEts-1 (AdTMEts-1) markedly inhibited angiogenesis in vivo within Matrigel plugs.
• The results demonstrate the potent anti-angiogenic capability of TMEts-1.

Conclusions:

• TMEts-1 functions as a dominant-negative inhibitor of Ets-1, effectively blocking its pro-angiogenic role.
• TMEts-1 represents a promising molecular tool for therapeutic inhibition of angiogenesis.
• Adenovirus-delivered TMEts-1 shows significant potential for controlling pathological angiogenesis.